secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001628280-24-022233
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q2 net loss $125.3M ($1.02/share) vs prior year net income $48.7M; revenue $0
--------------------------------------------------------------------------------

- Net loss of $125.3 million ($1.02 diluted loss per share) compared to net income of $48.7 million ($0.45 diluted EPS) in Q2 2023.
- Revenue was $0, down from $146.3 million a year ago, with no milestone or collaboration revenue recorded.
- R&D expenses rose to $101.1 million from $74.9 million; cash and investments totaled $523.1 million, boosted by $450 million stock offering.
- Received $50 million milestone from Royalty Pharma in Q3 for olpasiran Phase 3 enrollment completion (Amgen-conducted trial).
- Positive Phase 2 SHASTA-2 plozasiran data: 90.6% of patients achieved triglycerides <500 mg/dL at week 24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828024022233/0001628280-24-022233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828024022233/arwr-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-022233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer